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Studies of hospitalised COVID-19 patients have found inconsistencies in mortality associated with 
underlying respiratory conditions and inhaled corticosteroid (ICS) use. We sought to investigate this 
relationship using a national, multicentre, prospective cohort.   
Methods 
Prospective, multicentre UK cohort of hospitalised COVID-19 patients. Patients with asthma, chronic 
pulmonary disease (CPD), or both, were identified and stratified by age (years): <16, 16-49 and ≥50. 
In-hospital mortality was measured using multilevel Cox proportional hazards, adjusting for 
demographics, comorbidities and medications (ICS, short-acting-beta-agonists (SABA), long-acting-
beta-agonists (LABA)). Asthma patients using ICS+LABA+another asthma medication were considered 
‘severe’. 
Findings 
75,463 patients were included: <16 years, 860 patients (8.6% asthma); 16-49 years, 8,950 patients 
(20.9% asthma), ≥50 years, 65,653 patients (9.0% asthma, 15.6% CPD, 3.2% asthma & CPD). Asthma 
patients were significantly more likely to receive critical care, CPD patients were significantly less likely 
to. In patients 16-49 years, only those with severe asthma had a significant increase in mortality 
(adjusted HR (95%CI): no therapy=1.21 (0.78-1.88), SABA-only=1.03 (0.66-1.62), ICS-only=1.01 (0.68-
1.51), ICS+LABA=1.06 (0.70-1.61), severe=2.07 (1.35-3.18)). In patients ≥50 years, there was increased 
mortality associated with CPD and severe asthma. ICS use was associated with lower mortality 
(adjusted HR (95% CI): asthma+no_ICS=0.97 (0.90-1.04), asthma+ICS=0.87 (0.81-0.93), 
CPD+no_ICS=1.16 (1.11-1.21), CPD+ICS=1.10 (1.04-1.17), asthma+CPD+no_ICS=1.13 (1.00-1.27), 
asthma+CPD+ICS=0.98 (0.89-1.07). 
Interpretation 
Underlying respiratory conditions are common in hospitalised COVID-19 patients. Regardless of 
admission severity and comorbidities, asthma patients were more likely to receive critical care than 
patients without underlying respiratory disease; CPD patients were less likely to. Severe asthma in 
≥16-year olds was associated with increased mortality relative to other asthma patients. In patients 
≥50 years, ICS use in asthma was associated with lower mortality relative to patients without an 
underlying respiratory condition; CPD patients had significantly increased mortality but ICS use did not 
have a significant effect on mortality.   
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Evidence before this study 
Early case series, at the beginning of the COVID-19 pandemic, suggested the prevalence of hospitalised 
COVID-19 patients with chronic respiratory disease was lower than the prevalence in the local 
population. Subsequently, several studies have specifically addressed the risk of adverse COVID-19 
outcomes, including hospitalisation and death, in asthma and chronic obstructive pulmonary disease 
(COPD). Few observational studies have examined the effect of inhaled corticosteroids (ICS) on 
mortality. One large study, using the OpenSafely consortium which included primary care records 
linked to COVID-19 death data, found high-dose ICS use in asthma patients and any ICS use in COPD 
patients was associated with an increased mortality. They suggested the association could be 
explained, fully or in part, by unmeasured confounding due to disease severity.   
Added value of this study 
Our study uses the largest cohort of hospitalised COVID-19 patients worldwide, the International 
Severe Acute Respiratory and emerging Infection Consortium (ISARIC) WHO Clinical Characterisation 
Protocol UK (CCP-UK) study. We inform on two major questions for people with underlying respiratory 
conditions. First, we describe the patients including the level of care they received and their mortality 
risk, comparing across ages and between common respiratory conditions. We found asthma patients 
were significantly more likely to receive critical care and ventilatory support even after adjusting for 
severity on admission, age and comorbidities; in contrast, CPD patients were significantly less likely to 
receive critical care. CPD patients and those with severe asthma had increased mortality. Second, we 
measured the association of mortality with ICS use. In contrast to OpenSafely, we demonstrated that 
use of ICS within two weeks of admission was associated with lower mortality in asthma but had no 
effect on mortality in CPD.   
Implications of all the available evidence 
In the UK, there appears to be a disparity between patients with different respiratory conditions and 
the level of in-hospital care received, not accounted for by clinical severity, age or comorbidities. Both 
our secondary care study and the primary care OpenSafely study found patients with more severe 
asthma were at risk of increased mortality. Our study suggests that use of ICS within two weeks of 
admission may be beneficial, perhaps via a putative anti-inflammatory effect. The evidence from these 
two large observational cohorts report contrasting effects from ICS, although the timing of ICS use 
may have differed. Both studies are at risk of misclassification and confounding; the results of ongoing 







Coronavirus disease 2019 (COVID-19), caused by the virus SARS-CoV-2, was declared a pandemic on 
March 11th 2020, by the World Health Organisation (WHO). By the end of September 2020, there were 
over 1 million deaths, significant concern for a second wave of infections and a belief that the 
pandemic will not end for another two years.  
People with chronic obstructive pulmonary disease (COPD) and asthma were initially judged to be at 
substantial risk of developing severe COVID-19(1, 2). These putative risk factors were based on 
knowledge that respiratory viruses are a major cause of disease exacerbations and because both 
diseases are associated with deficient innate immune responses to respiratory virus infections, likely 
vital in defence against a novel virus(1, 3). With increasing time and an accumulation of observational 
data, it appears that COPD is a definitive risk factor for severe COVID-19 outcomes(4, 5). For people 
with asthma, the predisposition to morbidity and mortality from COVID-19 is less straightforward. 
Early large case series of patients hospitalised with COVID-19 found the proportion with asthma to be 
lower than that of the local population(6-8), unlike during the 2009 influenza pandemic(9). These 
findings suggested asthma was associated with reduced susceptibility to severe COVID-19, with 
behavioural, pharmacological and immunopathological explanatory mechanisms proposed(10, 11). 
More recent epidemiological studies have further complicated understanding, as some signify an 
association with severe COVID-19 disease(5, 12, 13), while others do not(4, 14-17).  
One mechanism postulated to correlate with protection is inhaled corticosteroid use (ICS)(10, 18). 
Experimental human and animal studies have shown that ICS use attenuates the expression of key 
SARS-CoV-2 related genes, in both asthma and COPD(19-21). Whilst two U.S. asthma cohorts found 
no association between ICS use and COVID-19 related hospitalisation, a large U.K. cohort found an 
increase in COVID-19 related mortality associated with high dose ICS use in asthma, and any ICS use 
in COPD(15, 22, 23). Understanding the impact of ICS is critical for respiratory patients. It was notable 
that at the beginning of the pandemic, in the UK, the demand for ICS prescriptions escalated to such 
an extent it caused distressing shortages. 
Using data from the International Severe Acute Respiratory and emerging Infection Consortium 
(ISARIC) WHO Clinical Characterisation Protocol UK (CCP-UK) study, we aimed to characterise people 
admitted with underlying respiratory disease, the level of care received, measure in-hospital 




The ISARIC WHO CCP-UK protocol was developed in 2009, with regular review and updates in response 
to potential threats posed by emerging infections. The study was activated in response to the SARS-
CoV-2 pandemic on 17th January 2020. This is an actively recruiting, prospective cohort study of 
hospitalised patients with strongly suspected or confirmed COVID-19 recruiting across England, 
Scotland and Wales. The protocol, revision history, case report forms, study information and consent 
forms are available online (https://isaric4c.net). Data and analysis scripts are available on request. 
Study population 
From 17th January until 3rd August 2020, patients admitted to hospital with a confirmed or highly 
suspected SARS-CoV-2 infection leading to COVID-19 disease were eligible for inclusion in this study. 
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Confirmation of SARS-CoV-2 was performed using reverse-transcriptase polymerase chain reaction 
(RT-PCR), the only testing modality available in the UK during the study period. Highly suspected but 
unproven cases were eligible for inclusion, given that SARS-CoV-2 was an emergent pathogen at time 
of protocol activation and confirmatory RT-PCR was contingent on local availability of tests. Patients 
who were admitted past the 3rd August 2020 were excluded to avoid bias from those who had not 
had adequate time to accrue an outcome. Follow-up of patients ended on 17th August. 
Ethical approval 
Ethical approval was given by the South Central-Oxford C Research Ethics Committee in England 
(reference 13/SC/0149), and by the Scotland A Research Ethics Committee (reference 20/SS/0028). 
The study was registered at https://www.isrctn.com/ISRCTN66726260. 
Variables 
Data were collected by clinical research staff using a standardised case report form and entered into 
a secure Research Electronic Data Capture secure online database. Data were captured across multiple 
timepoints, including at admission, during hospital stay (day 1, 3, 6 and 9) and discharge. 
Characteristics including age, sex, comorbidities; asthma, chronic pulmonary disease (CPD), chronic 
cardiac disease, chronic haematologic disease (excluding malignancy), chronic kidney disease, chronic 
neurological disease, HIV/AIDs, malignancy, liver disease, obesity, rheumatologic disorder and 
smoking history were captured. Physiological parameters at admission were recorded, including the 
components of the National Early Warning Score 2 (NEWS2); these last were categorised as low (<5), 
moderate (5-6) and severe (≥7) clinical risk. We captured medications entered as free-text and 
subsequently mapped this to drug preparations using data provided by the NHS Technology Reference 
data Update Distribution Service. Index of Multiple Deprivation (IMD, an area-based measure of 
relative deprivation) was determined using the area of the patient’s home (where the most deprived 
are represented by the 5th quintile). Where that was missing, a hospital-weighted average deprivation 
score was used. 
Patients with respiratory disease, recorded in the case report form as asthma or CPD (no asthma), 
were stratified into three age groups: <16 years, 16- 49 years, and ≥50 years. Asthma spans all ages 
but the potential for misclassification due to other similar conditions increases from around 50 years 
of age. Stratifying by age reduces the risk of this bias and helps control for age, one of the main 
confounders for assessing COVID-19 outcomes. Due to the small number of children, descriptive 
analysis only was carried out. Asthma patients under 50 years old were identified using the case report 
form, or by patients without CPD who were taking inhaled asthma medication (ICS, short-acting β2-
agonists (SABA), long-acting β2-agonists (LABA), theophylline or leukotriene receptor antagonists 
(LTRA)) within two weeks of admission. Patients prescribed ICS + LABA + another asthma medication 
(LAMA, LTRA or theophylline) were considered to have ‘severe’ asthma (equivalent to the highest 
steps in the asthma management stepwise approach). CPD patients were those that had entered CPD 
(no asthma) on the case report form. In patients over 50 years, those that had not entered asthma or 
CPD (no asthma) were classified as having no respiratory condition (Supplementary Table 1). 
Further breakdown of the respiratory diagnoses within the CPD category were not recorded but were 
mostly likely to be predominantly COPD.  
Outcomes 
The primary outcome was in-hospital survival from onset of symptoms, measured as time in days to 
death. Secondary outcomes, during the index hospital admission,  included any admission to critical 
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care (Level 3- Intensive Care Unit or Level 2 – High Dependency Unit), and whether the patient 
received invasive mechanical ventilation (IMV), non-invasive ventilation (NIV) or oxygen (O2).  
Statistical Analysis 
Categorical data were summarised as frequencies and percentages and tested using the Chi-square 
statistic, except for when cell counts were five or fewer, where Fisher’s exact was used (all p-values 
are based on non-missing values). For continuous data, normally distributed variables were 
summarised as mean (SD, standard deviation) and non-normally distributed variables as median (IQR, 
interquartile range). Continuous variables where appropriate were analysed using a two-sample 
Welch’s T-test for normally distributed data, or a Mann-Whitney U or Kruskall-Wallis for data that was 
not normally distributed.  
Time to in-hospital death (survival) was modelled using Cox proportional hazards regression and 
logistic regression was used for modelling of binary outcomes. For survival models, the reported date 
of symptom onset was taken as day zero and discharge from hospital was considered an absorbing 
state (once discharged, patients were considered no longer at risk of death). Discharge did not 
compete with death as discharged patients were not censored and included in the risk set until the 
end of follow-up. After building the survival models we confirmed the assumptions of proportional 
hazards were met by plotting the Schoenfeld residuals and inspecting for symmetry over time. An 
iterative modelling approach was adopted where clinically plausible variables which could explain 
differences in mortality were entered into preliminary multivariable models. We selected the final 
models through minimisation of the Akaike Information Criterion (AIC). Variables that did not reduce 
AIC were dropped to minimise over-fitting. Where data on predictor (explanatory) variables were 
missing, we used multiple imputation by chained equations to generate 5 imputed datasets with 5 
iterations of imputation per dataset. Models were then fitted on each imputed dataset and the final 
models pooled using Rubin’s rules. 
First order interactions were checked, and any significant interactions retained. Covariates included 
were age, sex, ethnicity, deprivation, obesity, smoking, chronic cardiac disease, chronic kidney disease 
and malignancy.  
Both survival models and logistic regression models took variation across healthcare facilities into 
account by using mixed effects models. Patient level risk factors were modelled as fixed effects and 
the healthcare facility as a random effect. We performed three post-hoc sensitivity analyses, first, 
excluding patients with obesity, second, excluding patients without a positive RT-PCR test result. Third, 
in the ≥50 years, including all medication strata (not only ICS) but excluding patients with missing 
variable for asthma or CPD. Effect estimates are presented as hazard ratios (HR) for time to death and 
odds ratios (OR) for binary outcome data, alongside their corresponding 95% confidence intervals. 
Statistical significance was taken at the level of P<0·05.  
Data were analysed using R version 3.6.3 (R Foundation for Statistical Computing, Vienna, AUT) using 
the tidyverse, finalfit and mice packages. 
Role of the funding source 
The sponsor had no role in the study design, collection, analysis, data interpretation or report writing. 
TMD, CIB, ABD and EMH had access to the raw data. The corresponding author had full access to all 





Up to 17th August 2020, 78,674 patients were enrolled into the ISARIC CCP-UK cohort across 258 
healthcare facilities; 75,463 patients had comorbidity data available (Figure 1). Chronic respiratory 
disease (including asthma and/or CPD) was the most prevalent comorbidity (20,196/75,463; 26.8%). 
97.4% of patients (73,500) had PCR positive SARS-CoV-2 infection. 
Patient characteristics  
Under 16 years old 
There were 860 children, <16 years, 786 (91.4%) without asthma and 74 (8.6%) with asthma. Patients 
with asthma were older, more likely to be of white ethnicity, but had similar clinical characteristics to 
children without asthma (Supplementary Table 2). Around forty percent were using ICS (41.9%). Five 
patients were using monoclonal antibodies for severe asthma. 
16 to 49 years old 
There were 8,950 patients, 16-49 years, 7,083 (79.1%) without asthma and 1,867 (20.9%) with asthma. 
Age was similar for patients with and without asthma (mean, years (SD): asthma=3879 (8.6), no 
asthma=38.9 years (8.6)) but there were more females, higher proportions of white ethnicity and 
obese, and similar proportion of smokers in those with asthma (Table 1 and Supplementary Table 3). 
The prevalence of other co-morbidities was low, with small differences between those with and 
without asthma. Just over half of asthma patients were using ICS (ICS only=22.7%, combination 
ICS+LABA=22.7%, severe=10.8%). Five patients were using monoclonal antibodies for severe asthma.  
50 years old and over 
There were 65,653 patients, ≥50 years, 47,398 (72.2%) patients without a respiratory condition, 5,918 
(9.0%) with asthma alone, 10,266 (15.6%) with CPD (no asthma) and 2,071 (3.2%) with co-diagnosis of 
asthma and CPD. Patients with asthma were slightly younger, more likely to be female and obese but 
less likely to be of white ethnicity or a current smoker, than patients with CPD (no asthma) (Table 2 
and Supplementary Table 4). Those with asthma were less likely to have chronic cardiac disease, but 
other comorbidities were of similar prevalence. There was a higher proportion of patients using ICS in 
those with asthma than those with CPD alone (asthma alone=61.7%, asthma & CPD=68.1%, CPD (no 
asthma)=41.3%).  
Symptoms and severity on admission (all age groups) 
Patients with a respiratory condition were significantly more likely to have dyspnoea, wheeze and 
cough, but in those aged ≥16 years, only around 1 in 7 presented with wheeze (Table 3 & 
Supplementary Table 5). In children, <16 years, 40% presented with wheeze (Supplementary Table 
5). In those aged ≥50 years, over two-thirds presented with dyspnoea, as compared to just over half 
of patients without a respiratory condition (Table 3).   
Asthma patients, aged ≥16 years, had a similar level of severity on admission to patients with no 
respiratory condition, whereas patients with CPD (with or without asthma) presented with higher 
NEWS2 scores (Table 3).  
Level of care during hospital admission (all age groups) 
No children (aged <16 years) with asthma died but ten were transferred to critical care 
(Supplementary Table 5). Asthma patients, aged 16-50 years and ≥50 years, were significantly more 
likely to receive critical care, NIV and oxygen than patients without a respiratory condition after 
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adjusting for age, gender, ethnicity, obesity, smoking and comorbidities (Table 4). Whereas, CPD 
patients, aged ≥50 years, were significantly less likely to receive critical care or IMV, but there was an 
increased association with NIV and oxygen supplementation, as compared to patients without a 
respiratory condition (Table 4). On additionally adjusting for NEWS2 score there was minimal change 
to effect estimates, except a reduction in adjusted OR for NIV use in CPD (no asthma) (adjusted 
OR=1.04, 95% CI 0.97-1.12) and CPD & asthma patients (adjusted OR=1.09, 95% CI 0.95-1.25). 
Survival  
In asthma (16-49 years) by asthma therapy 
6.5% of patients with asthma and 5.4% of patients without asthma died (Supplementary Figure 1). 
After adjusting for multiple risk factors, only asthma patients with severe asthma had higher rates of 
in-hospital mortality (adjusted HR (95%CI): no therapy=1.17 (0.73-1.86), SABA-only=0.99 (0.61-1.58), 
ICS-only=0.94 (0.62-1.43), ICS+LABA=1.02 (0.67-1.54), severe=1.96 (1.25-3.08)) (Figure 2 and 
Supplementary Table 6). 
In respiratory conditions (≥50 years) by ICS use only 
A high proportion of patients with CPD died (41.6%) during their hospital admission, compared to 
those with asthma (28.2%) or no underlying respiratory condition (34.0%) (Table 3 and 
Supplementary Figure 2). Asthma patients had a 13% significant reduction in mortality risk if they 
were using ICS compared to those with no underlying respiratory condition, but no reduction if they 
were not using ICS (asthma-no ICS: adjusted HR=0.97, 95% CI 0.89-1.05; asthma+ICS: adjusted 
HR=0.86, 95% CI 0.80-0.92) (Figure 3 and Supplementary Table 7). When stratifying on patients with 
asthma alone, patients with severe asthma had an increased mortality compared to those on no 
therapy (Supplementary Figure 3 and Supplementary Table 8). CPD patients (no asthma) had a 
statistically significant increase in mortality risk, regardless of ICS use, as compared to patients without 
an underlying respiratory condition (CPD-no-asthma-no-ICS: adjusted HR=1.16, 95% CI 1.12-1.22; CPD-
no-asthma + ICS: adjusted HR=1.10, 95% CI 1.04-1.16) (Figure 3 and Supplementary Table 7). Patients 
with CPD and asthma, had a non-significant increased mortality risk if they were not using ICS, as 
compared to patients without an underlying respiratory condition (CPD-with-asthma-no-ICS: adjusted 
HR=1.13, 95% CI 1.01-1.28; CPD-with-asthma + ICS: adjusted HR=0.97, 95% CI 0.89-1.06). 
On stratifying by NEWS2 score, in all strata and respiratory condition, there was a lower mortality rate 
in patients using ICS as compared to patients not using ICS (Supplementary Table 9).   
Sensitivity analyses 
After removing patients with obesity, associations with mortality did not differ from those found in 
the main analyses (Supplementary Figures 4 and 5). Only including patients with positive RT-PCR, did 
not affect associations found in the main analyses (Supplementary Figures 6 and 7). Bronchodilators, 
or number of long-acting inhalers used, did not affect the effect estimates in the CPD patients 
(Supplementary Figure 8). Modelling age as a continuous transformed variable, did not affect 
associations as compared to including age as a categorical variable (Supplementary Tables 10 & 11, 
Supplementary Figures 9 and 10). 
Effect of different ICS on survival (grouping together all adults with an underlying respiratory 
condition) 
After adjusting for mortality risk factors, beclometasone had a 9% significantly reduced risk of in-
hospital mortality compared to no ICS (adjusted HR=0.93, 95% CI 0.89-0.98); fluticasone and 
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ciclesonide did not have a significant association with mortality (Supplementary Figure 11 and 




The ISARIC CCP-UK is to our knowledge, the largest cohort of hospital admissions for COVID-19 
worldwide. In contrast to some other cohorts, we found that the proportion of people with asthma 
admitted to hospital with COVID-19 (8.6% <16 years, 20.9% in 16-49 years and 12.2% in ≥50 years) 
was considerably higher than the national prevalence of asthma which is around 7% for each age 
group(24). Patients with underlying respiratory conditions were more likely to present with 
respiratory symptoms, dyspnoea and cough, but wheeze was uncommon except in children with 
asthma (<16 years old).  
CPD patients had a high mortality rate of around 40% but were significantly less likely to receive critical 
care or invasive ventilatory support than patients with no underlying respiratory condition, even after 
considering age and comorbidities. In contrast, adult asthma patients were significantly more likely to 
receive critical care and ventilatory support. This did not seem to be associated with clinical severity 
on admission, as measured by NEWS2 score, suggesting other factors were contributing towards the 
decision to provide critical care. For example, it is likely these markers did not fully account for frailty, 
when treatment escalation discussions were held, and a low threshold for admitting patients with 
asthma to critical care for observation, given their potential to deteriorate quickly. All respiratory 
patients were more likely to receive NIV and oxygen supplementation than patients without an 
underlying respiratory condition, even after accounting for age, comorbidities and admission severity. 
Patients with the severe asthma (denoted by their maintenance medication use prior to admission), 
had worse survival than patients without an underlying respiratory condition. In all other asthma 
patients, there was no significant difference in mortality except in those using ICS, aged 50 years or 
more, who had decreased mortality. It is possible these differential effects with age and mortality are 
related to immune senescence, which can occur from 55 years of age(25). One aspect includes an 
increase in inflammation that may inhibit immunity to viruses or worsen hyperinflammation at the 
time of infection; ICS has been postulated to reverse this affect(26, 27). Another possibility is that ICS 
exhibits its apparent age preferential effect through inhibition of ACE2 as expression of ACE2 is 
relatively higher with older age(28).  
Our findings in asthma patients correspond with work from the OpenSafely primary care consortium. 
Using over 17 million UK medical records linked to COVID-19 deaths, they found only patients with 
severe asthma (defined by the prescription of oral corticosteroids in the past year) were predisposed 
to increased mortality(23). Another large study, using UK Biobank data from over 65,000 people with 
asthma (enrolled at ages 40-59 years), found non-allergic asthma, or asthma with a co-diagnosis of 
COPD, to be associated with increased risk of hospitalisation for COVID-19; while allergic asthma 
showed a non-significant association with reduced hospitalisation(13). These studies engaged large 
numbers but being observational were all susceptible to inherent misclassification of asthma, due to 
self-reporting or diagnosis by a non-specialist, as well as limited information on underlying asthma 
severity and phenotypes. Small case series, using well defined asthma patients (diagnosed by 
specialists with detailed medical records) found asthma to be associated with an increased risk of 
severe COVID-19(29, 30). We found asthma to be associated with an increased level of care, even after 
adjusting for clinical severity on admission, but not with an increased risk of death (except for those 
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with severe asthma); similar to findings with the 2009 influenza pandemic(9). In our study, we 
attempted to further refine asthma classification by using an age cut-off and, in the older cohort, 
separating those documented as having asthma alone from patients with asthma and another CPD.  
The first published cohorts of hospitalised COVID-19 patients from China, US and Europe, found a 
variable prevalence of COPD, sometimes below the expected population prevalence, leading to an 
initial debate about possible protection(10). Subsequently, the OpenSafely collaborative found COPD 
to be a highly significant risk factor, seemingly in agreement with the findings from ISARIC-CCP-UK 
which addressed patients with CPD, rather than COPD(4, 5). A possible mechanism for the increased 
susceptibility may be related to the elevated expression of ACE2 in the airway epithelial cells in COPD 
patients and smokers(31, 32) .  
The question of whether ICS use is protective is raised by studies demonstrating decreased ACE2 in 
sputum with ICS use in asthma and ICS-induced downregulation of ACE2 at gene and protein levels in 
COPD(19-21). The OpenSafely collaborative conducted an analysis, using an asthma cohort and a 
separate COPD cohort, and reported that ICS was not protective for COVID-19 related survival(23). 
Indeed, they reported worse outcomes associated with high dose ICS use in asthma, and all ICS use in 
COPD. However, further analyses revealed considerable residual confounding, thought to be 
unaccounted for respiratory disease severity(23). Their asthma findings are potentially in keeping with 
this study as although we could not address ICS dose, we found patients with more severe disease 
(more likely to be using high-dose ICS) had reduced survival. It is postulated that the timing of ICS use 
may be critical in terms of the effect of ICS on infection versus the effect on the host response to 
infection(18). In this regard our study patients reported using their medication within two weeks of 
admission, i.e. at the time of severe COVID-19. Pointedly, in the OpenSafely study patients could be 
prescribed ICS any time within four months before entering the study cohort. Our study also includes 
a different population, ISARIC CCP-UK only includes hospitalised patients with COVID-19, OpenSafely 
included the general population, those infected and not infected by SARS-CoV-2. Two US studies using 
electronic medical records from asthma patients only (n=1,526 and n=1,827) addressed the risk of 
COVID-19 hospitalisation(14, 22) - Wang et al also addressed critical care admission and death(33). 
Both studies found ICS use was not associated with hospitalisation, but Wang et al found there was a 
non-significant effect for reduced critical care admission and improved survival. A Korean study 
including 218 hospitalised asthma patients, found no significant association between mortality and 
any asthma medications in COVID-19 hospitalised patients(34).  
To date, there is no prior observational data addressing the impact of different ICS drugs. In-vitro data 
indicates that ciclesonide can suppress SARS-CoV-2 replication(35). Due to the small number of 
patients prescribed ciclesonide inhalers in the UK this analysis did not have sufficient power to assess 
its association with mortality. 
Limitations 
The dataset is not currently linked to primary or secondary care records, and where data were 
obtained from self-reporting (medication and diagnoses of conditions, including asthma), these could 
not be confirmed. This could have resulted in misclassification of the prescriptions and diagnoses. We 
also did not have information on the severity of the underlying respiratory condition, except by their 
admission medications. Information on the dose of inhaled corticosteroids was often missing, such 
that this variable was not used. We have assumed patients were using their prescribed medications 
on admission, this may not have been the case for some. For this reason, we were unable to classify 
the severity of asthma, except to assume those on three maintenance asthma medications in the two 
weeks before admission had more severe asthma than the other patients. We did not know the reason 
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for any oral corticosteroids that may have been prescribed pre-admission. Conditions not included on 
the study case report forms could not be evaluated separately, including atopy, and COPD and 
bronchiectasis which were likely included in the CPD (no asthma) category. Physiological 
measurements for clinical severity were limited to ones included in the NEWS2 score and were only 
available on admission. Finally, we were interested in the outcome of in-hospital mortality 
(incorporating palliative discharge), which could have led to some patients who were discharged and 
died in the community being missed. Our analysis used discharge as an absorbing state, considering 
all these patients as being alive, discharge is associated with outcome (i.e. is informative) and 
therefore should not be used as a censoring event in this analysis. This is a reasonable assumption give 
our methods of data collection, but it is a limitation. 
Conclusion 
Chronic respiratory disease was the most prevalent comorbidity in the ISARIC CCP-UK cohort. 
However, there was a disparity between different respiratory conditions and the level of in-hospital 
care received. CPD patients had a high level of mortality with a prevalence of 40% for in-hospital death. 
Only asthma patients with severe asthma had increased mortality compared to those without an 
underlying respiratory condition. Patients with asthma (aged 50 years or more) had a lower mortality 
risk if they had used ICS within two weeks of admission. These results confirm that many patients with 
existing respiratory conditions are high risk and should continue to take precautions against exposure 
to SARS-CoV-2. The role of ICS in COVID-19 remains unclear, but ICS protect against exacerbations of 






Figure 1. Flow diagram of patient by inclusion and exclusion criteria 
                 
Figure 2. Association between asthma and COVID-19 related mortality in 16-50 years old. 
SABA=short-acting beta-agonist, LABA=long-acting beta-agonist, ICS=inhaled corticosteroid, 
IMD=index of multiple deprivation 
 
Figure 3. Association between ICS use, respiratory condition and in-hospital mortality in ≥50 years 
old. CPD= chronic pulmonary disease, ICS=inhaled corticosteroid, IMD=index of multiple deprivation 
 
Supplementary Figure 1. Time to in-hospital death by asthma and asthma treatment. 
Supplementary Figure 2. Time to in-hospital death by respiratory condition and ICS. 
Supplementary Figure 3. Association between asthma and COVID-19 related mortality, by their 
asthma treatment, in patients aged 50 years and over. SABA=short-acting beta-agonist, LABA=long-
acting beta-agonist, ICS=inhaled corticosteroid, IMD=index of multiple deprivation 
Supplementary Figure 4. Association between asthma and COVID-19 related mortality in 16-50 years 
old; removing obese patients.  
Supplementary Figure 5. Association between ICS use, respiratory condition and in-hospital mortality 
in ≥50 years; removing obese patients.  
Supplementary Figure 6. Association between asthma and COVID-19 related mortality in 16-50 years 
old; including only RT-PCR positive patients.  
Supplementary Figure 7. Association between ICS use, respiratory condition and in-hospital mortality 
in ≥50 years; including only RT-PCR positive patients.  
Supplementary Figure 8. Association between ICS use, respiratory condition and in-hospital mortality 
in ≥50 years including all medication strata. 
Supplementary Figure 9. Association between ICS use, respiratory condition and in-hospital mortality 
in 16-50 years old, including age as a continuous transformed variable 
Supplementary Figure 10. Association between ICS use, respiratory condition and in-hospital 
mortality in ≥50 years old, including age as a continuous transformed variable 
Supplementary Figure 11 - Effect of different ICS on in-hospital mortality.  
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